Medications for Nonradiographic Axial Spondyloarthritis

4 results

  • Bimzelx

    (bimekizumab)
    UCB, Inc.
    Usage: BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.

  • Cimzia

    (certolizumab pegol)
    UCB, Inc.
    Usage: CIMZIA is indicated for treating moderate to severe Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults and eligible pediatric patients aged 2 years and older.

  • Rinvoq

    (Upadacitinib)
    AbbVie Inc.
    Usage: RINVOQ is indicated for adults and pediatric patients (2+) with various conditions, including moderately to severely active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, after inadequate response to TNF blockers.

  • Taltz

    (ixekizumab)
    Eli Lilly and Company
    Usage: TALTZ is indicated for the treatment of moderate-to-severe plaque psoriasis in patients aged 6 and older, as well as for adults with active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.